VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, January 7, 2026
Stock Comparison
Experian plc vs Eli Lilly and Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Experian plc
EXPN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Experian plc's moat claims, evidence, and risks.
View EXPN analysisEli Lilly and Company
LLY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Eli Lilly and Company's moat claims, evidence, and risks.
View LLY analysisComparison highlights
- Moat score gap: Experian plc leads (76 / 100 vs 66 / 100 for Eli Lilly and Company).
- Segment focus: Experian plc has 4 segments (67.2% in North America); Eli Lilly and Company has 5 segments (65.5% in Cardiometabolic Health).
- Moat breadth: Experian plc has 7 moat types across 4 domains; Eli Lilly and Company has 5 across 2.
Primary market context
Experian plc
North America
Consumer and business credit reporting, identity/fraud data and decision analytics, plus consumer credit/insurance marketplaces
North America
Financial institutions, insurers, auto lenders, healthcare providers, advertisers, consumers
Data/analytics provider and consumer marketplace operator
67.2%
Eli Lilly and Company
Cardiometabolic Health
Branded cardiometabolic pharmaceuticals (type 2 diabetes, obesity, and related metabolic/cardiovascular conditions; especially incretin therapies)
Global
Patients via prescribers; payers/PBMs; wholesaler & pharmacy channels
Drug developer, manufacturer, and marketer
65.5%
Side-by-side metrics
Moat coverage
Shared moat types
Experian plc strengths
Eli Lilly and Company strengths
Segment mix
Experian plc segments
Full profile >North America
Oligopoly
Latin America
Quasi-Monopoly
UK and Ireland
Oligopoly
EMEA and Asia Pacific
Competitive
Eli Lilly and Company segments
Full profile >Cardiometabolic Health
Oligopoly
Oncology
Competitive
Immunology
Competitive
Neuroscience
Competitive
Other
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.